Paid Search (SEM / PPC) Media Planning Checklist for Healthcare / Pharma Campaigns

Google implemented stricter pharmaceutical advertiser verification requirements in 2025. Brands advertising prescription medications must complete Google's Health Advertising certification, which includes business license verification, pharmacist or medical professional certification for OTC pharmacy advertisers, and compliance with Google's healthcare and medicines advertising policy. Allow 4–6 weeks for verification review. Running Rx product SEM without verification results in account suspension.

Google's healthcare advertising policies vary by product type: prescription drugs, OTC medications, clinical trials, telehealth services, and medical devices are each governed by different policy sections with distinct restrictions on targeting, ad copy, and landing page requirements. Review the specific policy section for your product category before keyword research and creative development. Policy violations that result in ad disapproval can take 5–10 business days to resolve, delaying critical flight timing.

Paid search ad copy for branded prescription drug terms is subject to FDA OPDP promotional regulations — even in the constrained space of a Google Ads headline and description. Ad copy cannot make superiority claims without supporting data, must not minimize risks relative to benefits, and must link to a landing page with the full brief summary (or quick link to ISI). Route all DTC Rx SEM copy through MLR review, maintaining approval documentation for FDA audit readiness.

DTC pharmaceutical SEM keyword architecture separates three intent levels: (1) unbranded condition queries ('what is plaque psoriasis', 'relapsing MS symptoms') for upper-funnel disease awareness; (2) unbranded treatment queries ('biologic for psoriasis', 'DMT for MS') for mid-funnel treatment consideration; and (3) branded drug name queries ('Skyrizi for psoriasis', 'Kesimpta cost') for lower-funnel direct brand consideration. Each tier requires different bid levels, creative messaging, and landing page destinations.

Unbranded condition queries ('do I have ADHD', 'symptoms of psoriasis', 'what causes dry eye disease') are not subject to branded promotional restrictions under FDA OPDP and can drive disease education content without the fair balance disclosure requirements of branded DTC ads. Build unbranded condition campaigns that direct to patient education resources or diagnosis discussion guides — these campaigns build the top-of-funnel patient pipeline that eventually converts through branded search.

Pharmaceutical brand terms attract significant non-commercial traffic: 'drug side effects,' 'class action lawsuit,' 'recall news,' 'generic availability,' 'mechanism of action for physicians.' Build negative keyword lists that block legal, safety concern, academic, and news-related queries from landing on DTC patient acquisition campaigns. The search term report for any pharma brand will reveal dozens of queries per month that should be negated immediately.

Queries like '[drug name] copay card,' '[drug name] patient assistance program,' '[drug name] cost without insurance' represent patients who have already made a treatment decision and are seeking financial access solutions. These are among the highest-conversion queries in pharmaceutical SEM — targeting them with copay card or patient support program CTAs captures patients at the moment of financial barrier removal. Set high CPC bids and direct to a dedicated copay card landing page.

Bidding on competitor drug brand names in SEM is a higher-risk strategy in pharmaceutical than in most verticals. FDA guidance suggests that branded drug terms in ad copy must accurately represent the advertised drug. Bidding on a competitor brand term while only advertising your own drug is generally permissible, but ad copy cannot mention the competitor drug name. Evaluate conquest SEM against the reputational and regulatory risk — some brand teams prohibit competitor drug conquesting entirely.

Physician-oriented searches ('first-line JAK inhibitor for RA,' 'prescribing information [drug name],' '[drug name] Phase 3 trial results') require entirely different ad copy and landing pages than patient DTC campaigns. HCP ad copy should reference clinical trial data, mechanism of action, and indication specificity. HCP landing pages should link to full prescribing information and clinical evidence summaries, not patient-facing brand sites. Mixing HCP and DTC campaign structures conflates messaging and confuses platform quality signals.

Bing's demographic profile over-indexes on professionals 45+ with advanced degrees — a composition that aligns well with specialty physician search behavior. Bing CPCs for clinical and HCP-targeted pharmaceutical queries run 20–35% below Google equivalents. Medical professionals searching clinical queries on workplace computers often default to Bing (via Edge browser in hospital/clinical settings) — this is a structural Bing opportunity that pharma planners routinely underutilize.

HCP SEM campaigns should track professional-specific conversion actions: prescribing information PDF downloads, clinical detail aid requests, e-sample requests, Medical Science Liaison (MSL) meeting booking, and speaker program registration. These actions are your HCP SEM KPIs, not patient-oriented form fills. Configure separate conversion goals in Google Ads for HCP-specific actions and set distinct Target CPA goals per HCP conversion type.

The pharma SEM conversion funnel has multiple micro-conversion steps: ad click → drug information site visit → patient support section visit → copay card page view → copay card enrollment start → copay card enrollment complete. Each step is a measurable conversion goal with its own dropout rate. Track all steps in GA4 and import as conversion milestones in Google Ads. This funnel visibility lets you identify whether SEM performance problems sit at the keyword/ad level or the landing page/support program level.

The most rigorous pharma SEM attribution methodology links Google Click ID (GCLID) data from paid search clicks to patient support program enrollment records (copay card activations, hub enrollments) and eventually to pharmacy claims data via patient support program vendor partnerships. This chain — GCLID → hub enrollment → NRx fill — is operationally complex but produces a true cost-per-patient-start metric that can be compared against other DTC channel ROI.

DTC CTV and linear TV campaigns for pharmaceutical brands drive branded drug name search queries measurably within days of air dates. Monitor Google Search Console and Google Ads impression data for branded drug name search volume weekly, segmented by national vs. key DMA markets. A CTV campaign that delivers meaningful coverage should produce 20–40% branded search volume lift within 2 weeks — this is your fastest available proxy for DTC media impact before NRx data becomes available.

Patients researching chronic condition treatments may take 2–6 months from initial search to first prescription fill. Default 30-day conversion windows in Google Ads massively undercount the contribution of pharmaceutical SEM to eventual patient starts. Set custom conversion windows at 90 days for chronic condition product campaigns. Document the window selection rationale for internal reporting consistency and MLR record keeping.

Physicians attending major specialty conferences (ACC for cardiology, ADA for diabetes, ASCO for oncology, AAD for dermatology) search for drug information and clinical data at elevated rates during and immediately after conference presentations featuring your drug. Build scheduled bid adjustments (+30–50%) on HCP clinical search terms in the 72 hours surrounding major conferences relevant to your indication. This captures the conference-driven prescriber research spike at its peak.